What Is Corticorelin? Definition and What Research Reports

Corticorelin is the international non-proprietary name for a synthetic version of corticotropin-releasing factor (CRF), also called corticotropin-releasing hormone (CRH) or corticoliberin. It is a 41-amino-acid peptide normally produced in the hypothalamus, where it acts on the anterior pituitary to trigger release of adrenocorticotropic hormone (ACTH), which in turn drives adrenal cortisol secretion — the top of what is usually described as the hypothalamic-pituitary-adrenal (HPA) axis. A drug-development profile of the molecule catalogued the many names it has appeared under, including ACTH RF, corticoliberin, human corticotropin-releasing hormone, ovine corticotrophin-releasing factor and the development name Xerecept (PMID 15230628). In the peptide literature the term "corticorelin" generally signals the manufactured peptide used as a research or diagnostic tool, as distinct from endogenous CRH measured in tissue or plasma.

This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about diagnosis, treatment or health decisions. Nothing here describes how any substance should be used.

What Class of Molecule It Is

Corticorelin belongs to the class of hypothalamic releasing peptides — small signalling peptides whose job is to instruct the pituitary gland. Structurally it is a single-chain polypeptide of 41 residues. Two sequence variants appear in the literature: the human sequence (human CRH, sometimes written hCRH) and the ovine sequence (oCRF), which differs by several amino acids and has a longer duration of action in some settings. The Drugs in R&D profile listed both the human and ovine forms under the corticorelin heading, reflecting that the name has been applied across both (PMID 15230628). The salt form most often named in oncology research is corticorelin acetate.

Where the Peptide Comes From

Endogenous CRF is produced by parvocellular neurons of the paraventricular nucleus of the hypothalamus and is also expressed in other brain regions and in peripheral tissues such as the placenta. Corticorelin itself is produced synthetically, which is why the literature routinely describes it as a "synthetic human corticotropin-releasing factor analog" — a phrasing used directly in a review of its investigation in peritumoral brain edema (PMID 21154169).

How the Term Is Used in Research

"Corticorelin" appears in three broad literature contexts:

• Endocrine diagnostic testing. As a stimulation agent in CRH tests that probe pituitary and adrenal responsiveness.
• Neuroscience and stress biology. As a probe of CRF signalling and its downstream effects on other neurotransmitter systems.
• Oncology supportive care. As corticorelin acetate, an investigational agent studied for swelling around brain tumours and for possible steroid-sparing effects.

Related terms readers may encounter

What the Published Literature Reports

Diagnostic stimulation testing

A retrospective review of children referred for clinical CRH stimulation testing reported that the peak cortisol response to corticotropin-releasing hormone was associated with age and body size, meaning that interpretation of a "normal" peak was not independent of the child's characteristics (PMID 26500680). Researchers framed this as relevant to how thresholds are applied in paediatric endocrine assessment rather than as a claim about any therapeutic effect.

Central nervous system signalling

A study in healthy individuals examined corticotropin-releasing hormone and dopamine release, investigating whether CRH administration influenced dopaminergic signalling in the human brain (PMID 27951520). The study sat within a broader line of stress-biology work using CRH as an experimental probe, and its findings were reported as mechanistic observations in a healthy research population.

Peritumoral brain edema and steroid sparing

The most sustained clinical development programme for corticorelin concerned swelling of brain tissue around tumours. Reviews described corticorelin acetate injections as an investigational approach for peritumoral brain edema, positioned as a possible alternative or adjunct to corticosteroids such as dexamethasone (PMID 19678803, PMID 21154169). A report in the Journal of Clinical Oncology described a steroid-sparing effect of corticorelin acetate in peritumoral cerebral edema and reported that this was associated with improvement in steroid-induced myopathy — that is, muscle weakness attributed to corticosteroid exposure (PMID 23382470). Researchers presented the steroid-sparing observation as the primary framing of the peptide's investigational role in that setting.

Preclinical tumour models

Animal work examined whether corticorelin had activity against tumours themselves rather than only against surrounding edema. One study compared corticotropin-releasing factor, dexamethasone and temozolomide for treatment efficacy and toxicity in U87 and C6 intracranial glioma models (PMID 21385926). Two further preclinical reports described corticorelin acetate as having antitumor activity alone and in combination with bevacizumab, one against human solid tumour models (PMID 20809121) and one against human brain tumour models (PMID 21187487). These were laboratory and animal findings; they were not reported as established clinical outcomes in patients.

Adverse Events: What Studies Report

The verified literature summarised here focused mainly on efficacy endpoints and diagnostic responses rather than on detailed safety tabulation. The glioma model comparison explicitly evaluated toxicity alongside treatment efficacy for corticotropin-releasing factor, dexamethasone and temozolomide in U87 and C6 intracranial tumours (PMID 21385926). In the clinical edema setting, the reported benefit described was a steroid-sparing effect associated with improvement in steroid-induced myopathy, which is a reduction in a corticosteroid-related harm rather than an absence of risk from the peptide itself (PMID 23382470). Drug-development profiling of the compound covered its regulatory and development history under its several names (PMID 15230628). Readers should not infer a complete safety picture from these summaries.

Common Points of Confusion

1. Corticorelin is not a corticosteroid. It is a releasing peptide upstream of ACTH and cortisol, not a steroid hormone itself. The brain-edema literature specifically contrasted it with dexamethasone (PMID 21385926).
2. Corticorelin is not corticotropin. Corticotropin (ACTH) is the pituitary hormone released downstream; corticorelin is the hypothalamic signal that prompts it.
3. Human and ovine forms are distinct. Both have been described under the corticorelin heading, and the literature distinguishes human corticotropin-releasing hormone from ovine corticotrophin-releasing factor (PMID 15230628).
4. Investigational status is not the same as routine availability. Much of the oncology-related work described corticorelin acetate as investigational (PMID 19678803).

This entry is definitional. It does not describe protocols, quantities, schedules or administration of any kind, and no part of it should be read as guidance. Anyone with a clinical question about CRH testing, brain edema or corticosteroid exposure should raise it with a licensed physician.

References

• Corticorelin: ACTH RF, corticoliberin, corticotrophin-releasing hormone, corticotropin-releasing factor, human corticotropin-releasing hormone, ovine corticotrophin-releasing factor, Xerecept (Drugs in R&D, 2004)
• Corticotropin-releasing hormone and dopamine release in healthy individuals (Psychoneuroendocrinology, 2017)
• Peak cortisol response to corticotropin-releasing hormone is associated with age and body size in children referred for clinical testing: a retrospective review (International Journal of Pediatric Endocrinology, 2015)
• Corticorelin acetate injections for the treatment of peritumoral brain edema (Expert Opinion on Investigational Drugs, 2009)
• Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema (Current Opinion in Molecular Therapeutics, 2010)
• Steroid-sparing effect of corticorelin acetate in peritumoral cerebral edema is associated with improvement in steroid-induced myopathy (Journal of Clinical Oncology, 2013)
• Comparison of corticotropin-releasing factor, dexamethasone, and temozolomide: treatment efficacy and toxicity in U87 and C6 intracranial gliomas (Clinical Cancer Research, 2011)
• Corticorelin acetate, a synthetic corticotropin-releasing factor with preclinical antitumor activity, alone and with bevacizumab, against human solid tumor models (Cancer Chemotherapy and Pharmacology, 2011)
• Corticorelin acetate, a synthetic corticotropin-releasing factor with preclinical antitumor activity, alone and with bevacizumab, against human brain tumor models (Anticancer Research, 2010)